耐碳青霉烯类肠杆菌血流感染研究进展
Research progress of carbapenem-resistant Enterobacteriaceae bloodstream infection
邢康齐 1薛庆节 2石继魁3
作者信息
- 1. 济宁医学院临床医学院,济宁 272000
- 2. 济宁医学院基础医学院,济宁 272000
- 3. 济宁市第一人民医院重症医学科,济宁 272011
- 折叠
摘要
耐碳青霉烯类肠杆菌(carbapenem-resistant Enterobacteriaceae,CRE)感染情况日益严重,其血流感染死亡率高,常出现多种抗生素耐药,原因在于多个耐药机制作用,实验室检测在其治疗中发挥较大作用,抗感染治疗与非耐药类细菌感染相比疗效差,治疗方案各有不同且争议颇多.产碳青霉烯酶是临床常见的耐药机制之一,也是最主要的,可以通过实验室检测出具体产酶类型,以便临床医师了解状况,高效应用抗菌药物.参考国内外耐碳青霉烯类肠杆菌血流感染(carbapenem-resistant Enterobacteriaceae bloodstream infection,CRE-BSI)的最新研究进展,本文就它的耐药机制、实验室检测、治疗方面做一综述,以期更好指导临床合理规范用药,优化现有治疗方案.
Abstract
Infection with carbapenem-resistant Enterobacteriaceae(CRE)is becoming increasingly serious with a high mortality rate in bloodstream infections.Multiple antibiotic resistance is common due to the action of multiple resist-ance mechanisms.Laboratory tests play an important role in treatment.The efficacy of anti-infection treatment is poor compared with non-drug-resistant bacterial infections,and treatment regimens are variable and controversial.Carbapene-mase production is one of the most common mechanisms of drug resistance in clinical practice,and it is also the most im-portant.Certain types of enzyme production can be detected in the laboratory,allowing clinicians to understand the status and effectively use antibacterial drugs.Referring to the recent research progress in carbapenem-resistant Enterobacteri-aceae bloodstream infections(CRE-BSI)at home and abroad,this paper examines the resistance mechanism,laboratory investigation and treatment to better guide clinical rational and standardized drug use and optimize the existing treatment plan.
关键词
碳青霉烯耐药/血流感染/耐药机制/实验室检测/治疗Key words
Carbapenem-resistance/Bloodstream infection/Resistance mechanism/Laboratory detection/Treatment引用本文复制引用
基金项目
山东省重点研发计划项目(2018GSF118137)
山东省医药卫生科技项目(202319010449)
济宁市重点研发计划项目(2023YXNS106)
出版年
2024
NETL
NSTL
万方数据